Lumos Pharma Stock Performance
| LUMO Stock | USD 4.30 0.02 0.46% |
On a scale of 0 to 100, Lumos Pharma holds a performance score of 4. The company secures a Beta (Market Risk) of -0.68, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Lumos Pharma are expected to decrease at a much lower rate. During the bear market, Lumos Pharma is likely to outperform the market. Please check Lumos Pharma's semi variance, and the relationship between the treynor ratio and daily balance of power , to make a quick decision on whether Lumos Pharma's current price movements will revert.
Risk-Adjusted Performance
4 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Lumos Pharma are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of very weak primary indicators, Lumos Pharma displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.46) | Five Day Return (1.38) | Year To Date Return 33.54 | Ten Year Return (88.99) | All Time Return (39.27) |
Last Split Factor 1:9 | Dividend Date 2020-03-19 | Last Split Date 2020-03-19 |
1 | Short Interest in Lumos Pharma, Inc. Decreases By 33.3 | 09/17/2024 |
2 | Acquisition by Schuchart Aaron of 7805 shares of Lumos Pharma at 10.13 subject to Rule 16b-3 | 10/22/2024 |
3 | Shareholder Alert Ademi LLP Investigates Whether Lumos Pharma, Inc. Is Obtaining a Fair Price for Its Public Shareholders | 10/23/2024 |
4 | DPV set to acquire Lumos Pharma for 38m - Pharmaceutical Technology | 10/24/2024 |
5 | Disposition of 1593 shares by John McKew of Lumos Pharma at 3.28 subject to Rule 16b-3 | 10/25/2024 |
6 | Acquisition by Lalande Kevin M. of 4981 shares of Lumos Pharma at 10.4962 subject to Rule 16b-3 | 11/01/2024 |
7 | Lumos Pharma Faces Uncertainty as CVRs Risk Expiring Worthless Post-Merger - MSN | 11/20/2024 |
8 | Acquisition by Zoth Lota S. of 367 shares of Lumos Pharma subject to Rule 16b-3 | 11/22/2024 |
| Begin Period Cash Flow | 56 M |
Lumos |
Lumos Pharma Relative Risk vs. Return Landscape
If you would invest 390.00 in Lumos Pharma on August 30, 2024 and sell it today you would earn a total of 40.00 from holding Lumos Pharma or generate 10.26% return on investment over 90 days. Lumos Pharma is currently generating 0.2075% in daily expected returns and assumes 3.3541% risk (volatility on return distribution) over the 90 days horizon. In different words, 29% of stocks are less volatile than Lumos, and 96% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Lumos Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lumos Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Lumos Pharma, and traders can use it to determine the average amount a Lumos Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0619
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | LUMO | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.35 actual daily | 29 71% of assets are more volatile |
Expected Return
| 0.21 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Lumos Pharma is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Lumos Pharma by adding it to a well-diversified portfolio.
Lumos Pharma Fundamentals Growth
Lumos Stock prices reflect investors' perceptions of the future prospects and financial health of Lumos Pharma, and Lumos Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Lumos Stock performance.
| Return On Equity | -1.73 | ||||
| Return On Asset | -0.7 | ||||
| Operating Margin | (10.52) % | ||||
| Current Valuation | 24.02 M | ||||
| Shares Outstanding | 8.65 M | ||||
| Price To Earning | (2.37) X | ||||
| Price To Book | 7.60 X | ||||
| Price To Sales | 16.87 X | ||||
| Revenue | 2.05 M | ||||
| Gross Profit | 1.52 M | ||||
| EBITDA | (36.57 M) | ||||
| Net Income | (34.03 M) | ||||
| Cash And Equivalents | 79.51 M | ||||
| Cash Per Share | 9.49 X | ||||
| Total Debt | 585 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 17.59 X | ||||
| Book Value Per Share | 0.57 X | ||||
| Cash Flow From Operations | (31.09 M) | ||||
| Earnings Per Share | (4.28) X | ||||
| Market Capitalization | 37.19 M | ||||
| Total Asset | 40.64 M | ||||
| Retained Earnings | (161.52 M) | ||||
| Working Capital | 33.01 M | ||||
| Current Asset | 115.78 M | ||||
| Current Liabilities | 14.4 M | ||||
About Lumos Pharma Performance
By examining Lumos Pharma's fundamental ratios, stakeholders can obtain critical insights into Lumos Pharma's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Lumos Pharma is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 54.70 | 57.43 | |
| Return On Tangible Assets | (0.84) | (0.80) | |
| Return On Capital Employed | (1.09) | (1.03) | |
| Return On Assets | (0.84) | (0.80) | |
| Return On Equity | (1.25) | (1.18) |
Things to note about Lumos Pharma performance evaluation
Checking the ongoing alerts about Lumos Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Lumos Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Lumos Pharma had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 2.05 M. Net Loss for the year was (34.03 M) with profit before overhead, payroll, taxes, and interest of 1.52 M. | |
| Lumos Pharma currently holds about 79.51 M in cash with (31.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.49, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Lumos Pharma has a strong financial position based on the latest SEC filings | |
| Roughly 33.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Zoth Lota S. of 367 shares of Lumos Pharma subject to Rule 16b-3 |
- Analyzing Lumos Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Lumos Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Lumos Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Lumos Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Lumos Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Lumos Pharma's stock. These opinions can provide insight into Lumos Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lumos Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lumos Pharma. If investors know Lumos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lumos Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.28) | Revenue Per Share 0.27 | Quarterly Revenue Growth 102.714 | Return On Assets (0.70) | Return On Equity (1.73) |
The market value of Lumos Pharma is measured differently than its book value, which is the value of Lumos that is recorded on the company's balance sheet. Investors also form their own opinion of Lumos Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lumos Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lumos Pharma's market value can be influenced by many factors that don't directly affect Lumos Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lumos Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lumos Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lumos Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.